{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,3]],"date-time":"2026-10-03T14:09:23Z","timestamp":1791036563903,"version":"4.1.0"},"reference-count":32,"publisher":"Springer Science and Business Media LLC","issue":"1","content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Malar J"],"published-print":{"date-parts":[[2011,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Background<\/jats:title><jats:p>The development and spread of drug resistant<jats:italic>Plasmodium falciparum<\/jats:italic>strains is a major concern and novel anti-malarial drugs are, therefore, needed. Ferroquine is a ferrocenic derivative of chloroquine with proven anti-malarial activity against chloroquine-resistant and -sensitive<jats:italic>P. falciparum<\/jats:italic>laboratory strains.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>Adult young male aged 18 to 45 years, asymptomatic carriers of<jats:italic>P. falciparum<\/jats:italic>, were included in two-dose escalation, double-blind, randomized, placebo-controlled Phase I trials, a single dose study and a multiple dose study aiming to evaluate oral doses of ferroquine from 400 to 1,600 mg.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Overall, 54\/66 patients (40 and 26 treated in the single and multiple dose studies, respectively) experienced at least one adverse event, 15 were under placebo. Adverse events were mainly gastrointestinal symptoms such as abdominal pain (16), diarrhoea (5), nausea (13), and vomiting (9), but also headache (11), and dizziness (5). A few patients had slightly elevated liver parameters (10\/66) including two patients under placebo. Moderate changes in QTc and morphological changes in T waves were observed in the course of the study. However, no adverse cardiac effects with clinical relevance were observed.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>These phase I trials showed that clinically, ferroquine was generally well-tolerated up to 1,600 mg as single dose and up to 800 mg as repeated dose in asymptomatic young male with<jats:italic>P. falciparum<\/jats:italic>infection. Further clinical development of ferroquine, either alone or in combination with another anti-malarial, is highly warranted and currently underway.<\/jats:p><\/jats:sec>","DOI":"10.1186\/1475-2875-10-53","type":"journal-article","created":{"date-parts":[[2011,3,2]],"date-time":"2011-03-02T03:02:53Z","timestamp":1299034973000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":53,"title":["Phase I randomized dose-ascending placebo-controlled trials of ferroquine - a candidate anti-malarial drug - in adults with asymptomatic Plasmodium falciparum infection"],"prefix":"10.1186","volume":"10","author":[{"given":"Ghyslain","family":"Mombo-Ngoma","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian","family":"Supan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthias P","family":"Dal-Bianco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michel A","family":"Missinou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pierre-Blaise","family":"Matsiegui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carmen L","family":"Ospina Salazar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saadou","family":"Issifou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Ter-Minassian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Ramharter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maryvonne","family":"Kombila","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter G","family":"Kremsner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bertrand","family":"Lell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2011,3,1]]},"reference":[{"key":"1631_CR1","doi-asserted-by":"publisher","first-page":"2619","DOI":"10.1056\/NEJMc0805011","volume":"359","author":"H Noedl","year":"2008","unstructured":"Noedl H, Se Y, Schaecher K, Smith BL, Socheat D, Fukuda MM: Evidence of artemisinin-resistant malaria in western Cambodia. N Engl J Med. 2008, 359: 2619-10.1056\/NEJMc0805011.","journal-title":"N Engl J Med"},{"key":"1631_CR2","doi-asserted-by":"publisher","first-page":"3715","DOI":"10.1021\/jm970401y","volume":"40","author":"C Biot","year":"1997","unstructured":"Biot C, Glorian G, Maciejewski LA, Brocard JS, Domarle O, Blampain G, Millet P, Georges AJ, Abessolo H, Dive D, Lebibi J: Synthesis and antimalarial activity in vitro and in vivo of a new ferrocene-chloroquine analogue. J Med Chem. 1997, 40: 3715-3718. 10.1021\/jm970401y.","journal-title":"J Med Chem"},{"key":"1631_CR3","doi-asserted-by":"publisher","first-page":"2844","DOI":"10.1016\/S0968-0896(99)00224-2","volume":"7","author":"C Biot","year":"1999","unstructured":"Biot C, Delha\u00ebs L, N'Diaye CM, Maciejewski LA, Camus D, Dive D, Brocard JS, Dive D: Synthesis and antimalarial activity in vitro of potential metabolites of ferrochloroquine and related compounds. Bioorg Med Chem. 1999, 7: 2844-10.1016\/S0968-0896(99)00224-2.","journal-title":"Bioorg Med Chem"},{"key":"1631_CR4","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1007\/s004360000317","volume":"87","author":"L Delha\u00ebs","year":"2001","unstructured":"Delha\u00ebs L, Abessolo H, Biot C, Berry L, Delcourt P, Maciejewski L, Brocard J, Camus D, Dive D: In vitro and in vivo antimalarial activity of ferrochloroquine, a ferrocenyl analogue of chloroquine against chloroquine resistant malaria parasites. Parasitol Res. 2001, 87: 239-244.","journal-title":"Parasitol Res"},{"key":"1631_CR5","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1128\/AAC.42.3.540","volume":"42","author":"O Domarle","year":"1998","unstructured":"Domarle O, Blampain G, Agnaniet H, Nzadiyabi T, Lebibi J, Brocard J, Maciejewski L, Biot C, Georges AJ, Millet P: In vitro antimalarial activity of a new organometallic analog, ferrocene-chloroquine. Antimicrob Agents Chemother. 1998, 42: 540-544.","journal-title":"Antimicrob Agents Chemother"},{"key":"1631_CR6","doi-asserted-by":"publisher","first-page":"1021","DOI":"10.1093\/jac\/dkg161","volume":"51","author":"C Atteke","year":"2003","unstructured":"Atteke C, Ndong JM, Aubouy A, Maciejewski L, Brocard J, Lebibi J, Deloron P: In vitro susceptibility to a new antimalarial organometallic analogue, ferroquine, of Plasmodium falciparum isolates from the Haut-Ogooue region of Gabon. J Antimicrob Chemother. 2003, 51: 1021-1024. 10.1093\/jac\/dkg161.","journal-title":"J Antimicrob Chemother"},{"key":"1631_CR7","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1093\/jac\/48.2.179","volume":"48","author":"B Pradines","year":"2001","unstructured":"Pradines B, Fusai T, Daries W, Laloge V, Rogier C, Millet P, Panconi E, Kombila M, Parzy D: Ferrocene-chloroquine analogues as antimalarial agents: in vitro activity of ferrochloroquine against 103 Gabonese isolates of Plasmodium falciparum. J Antimicrob Chemother. 2001, 48: 179-184. 10.1093\/jac\/48.2.179.","journal-title":"J Antimicrob Chemother"},{"key":"1631_CR8","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1046\/j.1365-3156.2002.00848.x","volume":"7","author":"B Pradines","year":"2002","unstructured":"Pradines B, Tall A, Rogier C, Spiegel A, Mosnier J, Marrama L, Fusai T, Millet P, Panconi E, Trape JF, Parzy D: In vitro activities of ferrochloroquine against 55 Senegalese isolates of Plasmodium falciparum in comparison with those of standard antimalarial drugs. Trop Med Int Health. 2002, 7: 265-270. 10.1046\/j.1365-3156.2002.00848.x.","journal-title":"Trop Med Int Health"},{"key":"1631_CR9","doi-asserted-by":"publisher","first-page":"1595","DOI":"10.1086\/522160","volume":"196","author":"MP Grobusch","year":"2007","unstructured":"Grobusch MP, Lell B, Schwarz NG, Gabor J, D\u00f6rnemann J, P\u00f6tschke M, Oyakhirome S, Kiessling GC, Necek M, Langin MU, Klouwenberg PK, Klopfer A, Naumann B, Altun H, Agnandji ST, Goesch J, Decker M, Salazar CL, Supan C, Kombila DU, Borchert L, Koster KB, Pongratz P, Adegnika AA, Glasenapp I, Issifou S, Kremsner PG: Intermittent preventive treatment against malaria in infants in Gabon--a randomized, double-blind, placebo-controlled trial. J Infect Dis. 2007, 196: 1595-1602. 10.1086\/522160.","journal-title":"J Infect Dis"},{"issue":"Suppl 3","key":"1631_CR10","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1007\/s00508-007-0857-5","volume":"119","author":"M Ramharter","year":"2007","unstructured":"Ramharter M, Adegnika AA, Agnandji ST, Matsiegui PB, Grobusch MP, Winkler S, Graninger W, Krishna J, Yazdanbakhsh M, Mordmueller B, Lell B, Missinou MA, Mavoungou E, Issifou S, Kremsner PG: History and perspectives of medical research at the Albert Schweitzer Hospital in Lambar\u00e9n\u00e9, Gabon. Wiener Klinische Wochenschrift\/Middle European Journal of Medicine. 2007, 119 (Suppl 3): 8-12. 10.1007\/s00508-007-0857-5.","journal-title":"Wiener Klinische Wochenschrift\/Middle European Journal of Medicine"},{"key":"1631_CR11","doi-asserted-by":"crossref","first-page":"939","DOI":"10.4269\/ajtmh.2007.77.939","volume":"77","author":"MP Dal-Bianco","year":"2007","unstructured":"Dal-Bianco MP, K\u00f6ster KB, Kombila UD, Kun JFK, Grobusch MP, Mombo-Ngoma G, Matsiegui PB, Supan C, Ospina Salazar CL, Missinou MA, Issifou S, Lell B, Kremsner PG: High Prevalence of Asymptomatic Plasmodium falciparum Infection in Gabonese Adults. Am J Trop Med Hyg. 2007, 77: 939-942.","journal-title":"Am J Trop Med Hyg"},{"key":"1631_CR12","doi-asserted-by":"publisher","first-page":"901","DOI":"10.1086\/381785","volume":"189","author":"S Borrmann","year":"2004","unstructured":"Borrmann S, Adegnika AA, Matsiegui PB, Issifou S, Schindler A, Mawili-Mboumba DP, Baranek T, Wiesner J, Jomaa H, Kremsner PG: Fosmidomycin-clindamycin for Plasmodium falciparum infections in African children. J Infect Dis. 2004, 189: 901-908. 10.1086\/381785.","journal-title":"J Infect Dis"},{"key":"1631_CR13","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1016\/0035-9203(92)90414-8","volume":"86","author":"C Chang","year":"1992","unstructured":"Chang C, Lin-Hua T, Jantanavivat C: Studies on a new antimalarial compound: pyronaridine. Trans R Soc Trop Med Hyg. 1992, 86: 7-10. 10.1016\/0035-9203(92)90414-8.","journal-title":"Trans R Soc Trop Med Hyg"},{"key":"1631_CR14","doi-asserted-by":"publisher","first-page":"e6.oi:10.1371\/j","DOI":"10.1371\/journal.pctr.0020006","volume":"2","author":"F Mzayek","year":"2007","unstructured":"Mzayek F, Deng H, Mather FJ, Wasilevich EC, Liu H, Hadi CM, Chansolme DH, Murphy HA, Melek BH, Tenaglia AN, Mushatt DM, Dreisbach AW, Lertora JJL, Krogstad DJ: Randomized dose-ranging controlled trial of AQ-13, a candidate antimalarial, and chloroquine in healthy volunteers. PLoS Clin Trials. 2007, 2: e6.oi:10.1371\/journal.pctr.0020006-10.1371\/journal.pctr.0020006.","journal-title":"PLoS Clin Trials"},{"key":"1631_CR15","doi-asserted-by":"publisher","first-page":"1869","DOI":"10.1128\/AAC.01448-06","volume":"51","author":"S Oyakhirome","year":"2007","unstructured":"Oyakhirome S, Issifou S, Pongratz P, Barondi F, Ramharter M, Kun JFK, Missinou MA, Lell B, Kremsner PG: Randomized controlled trial of fosmidomycin-clindamycin versus sulfadoxine-pyrimethamine in the treatment of Plasmodium falciparum malaria. Antimicrob Agents Chemother. 2007, 51: 1869-1871. 10.1128\/AAC.01448-06.","journal-title":"Antimicrob Agents Chemother"},{"key":"1631_CR16","doi-asserted-by":"crossref","first-page":"39","DOI":"10.4269\/ajtmh.2002.67.39","volume":"67","author":"M Ramharter","year":"2002","unstructured":"Ramharter M, Noedl H, Thimasarn K, Wiedermann G, Wernsdorfer G, Wernsdorfer WH: In vitro activity of tafenoquine alone and in combination with artemisinin against Plasmodium falciparum. Am J Trop Med Hyg. 2002, 67: 39-43.","journal-title":"Am J Trop Med Hyg"},{"key":"1631_CR17","doi-asserted-by":"publisher","first-page":"1777","DOI":"10.1086\/430309","volume":"40","author":"M Ramharter","year":"2005","unstructured":"Ramharter M, Oyakhirome S, Klein Klouwenberg P, Ad\u00e9gnika AA, Agnandji ST, Missinou MA, Matsi\u00e9gui PB, Mordm\u00fcller B, Borrmann S, Kun JFK, Lell B, Krishna S, Graninger W, Issifou I, Kremsner PG: Artesunate-clindamycin versus quinine-clindamycin in the treatment of Plasmodium falciparum malaria: a randomized controlled trial. Clin Infect Dis. 2005, 40: 1777-1784. 10.1086\/430309.","journal-title":"Clin Infect Dis"},{"key":"1631_CR18","doi-asserted-by":"publisher","first-page":"911","DOI":"10.1086\/591096","volume":"198","author":"M Ramharter","year":"2008","unstructured":"Ramharter M, Kurth F, Schreier AC, Nemeth J, Glasenapp I, B\u00e9lard S, Schlie M, Kammer J, Koumba PK, Cisse B, Mordm\u00fcller B, Lell B, Issifou S, Oeuvray C, Fleckenstein L, Kremsner PG: Fixed-dose pyronaridine-artesunate combination for treatment of uncomplicated falciparum malaria in pediatric patients in Gabon. J Infect Dis. 2008, 198: 911-919. 10.1086\/591096.","journal-title":"J Infect Dis"},{"issue":"Suppl 2","key":"1631_CR19","doi-asserted-by":"publisher","first-page":"s71","DOI":"10.1007\/s00436-002-0770-9","volume":"90","author":"J Wiesner","year":"2003","unstructured":"Wiesner J, Borrmann S, Jomaa H: Fosmidomycin for the treatment of malaria. Parasitol Res. 2003, 90 (Suppl 2): s71-76. 10.1007\/s00436-002-0770-9. Review","journal-title":"Parasitol Res"},{"key":"1631_CR20","doi-asserted-by":"publisher","first-page":"1565","DOI":"10.1056\/NEJMra043207","volume":"352","author":"JK Baird","year":"2005","unstructured":"Baird JK: Effectiveness of antimalarial drugs. N Engl J Med. 2005, 352: 1565-1577. 10.1056\/NEJMra043207.","journal-title":"N Engl J Med"},{"key":"1631_CR21","unstructured":"Drugs for rheumatoid arthritis. Med Lett Drugs Ther. 2000, 42: 57-64."},{"key":"1631_CR22","unstructured":"Drugs for parasitic infections. Med Lett Drugs Ther. 2004, 46: 1-12."},{"key":"1631_CR23","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1080\/00034983.1998.11813289","volume":"93","author":"HM McIntosh","year":"1998","unstructured":"McIntosh HM, Greenwood BM: Chloroquine or amodiaquine combined with sulfadoxine-pyrimethamine as a treatment for uncomplicated malaria--A systematic review. Ann Trop Med Parasitol. 1998, 93: 265-270.","journal-title":"Ann Trop Med Parasitol"},{"key":"1631_CR24","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1016\/S0035-9203(03)00014-2","volume":"98","author":"HY Mying","year":"2004","unstructured":"Mying HY, Tipmanee P, Nosten F, Day NP, Pukrittayakamee S, Looareesuwan S, White NJ: A systematic overview of published antimalarial drug trials. Trans R Soc Trop Med Hyg. 2004, 98: 73-81. 10.1016\/S0035-9203(03)00014-2.","journal-title":"Trans R Soc Trop Med Hyg"},{"key":"1631_CR25","doi-asserted-by":"publisher","first-page":"25","DOI":"10.2165\/00002018-200427010-00003","volume":"27","author":"WRJ Taylor","year":"2004","unstructured":"Taylor WRJ, White NJ: Antimalarial drug toxicity: A review. Drug Safety. 2004, 27: 25-61. 10.2165\/00002018-200427010-00003.","journal-title":"Drug Safety"},{"key":"1631_CR26","doi-asserted-by":"publisher","first-page":"800","DOI":"10.1056\/NEJM199609123351107","volume":"335","author":"NJ White","year":"1996","unstructured":"White NJ: The treatment of malaria. N Engl J Med. 1996, 335: 800-806. 10.1056\/NEJM199609123351107.","journal-title":"N Engl J Med"},{"key":"1631_CR27","doi-asserted-by":"publisher","first-page":"583","DOI":"10.1136\/ard.57.10.582","volume":"57","author":"JA Avina-Zubieta","year":"1998","unstructured":"Avina-Zubieta JA, Galindo-Rodriguez G, Newman S, Suarez-Almazor ME, Russell AS: Long-term effectiveness of antimalarial drugs in rheumatic diseases. Ann Rheum Dis. 1998, 57: 583-587. 10.1136\/ard.57.10.582.","journal-title":"Ann Rheum Dis"},{"key":"1631_CR28","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1007\/s002109900185","volume":"361","author":"DE Benavides-Haro","year":"2000","unstructured":"Benavides-Haro DE, Sanchez-Chapula JA: Chloroquine blocks the background potassium current in guinea pig atrial myocytes. Arch Pharmacol. 2000, 361: 311-318. 10.1007\/s002109900185.","journal-title":"Arch Pharmacol"},{"key":"1631_CR29","first-page":"83","volume":"45","author":"MD Bustos","year":"1994","unstructured":"Bustos MD, Gay F, Diquet B, Thomare P, Warot D: The pharmacokinetics and electrocardiographic effects of chloroquine in healthy subjects. Trop Med Parasitol. 1994, 45: 83-86.","journal-title":"Trop Med Parasitol"},{"key":"1631_CR30","doi-asserted-by":"publisher","first-page":"877","DOI":"10.1016\/S0140-6736(95)92711-5","volume":"346","author":"JL Clemessy","year":"1995","unstructured":"Clemessy JL, Favier C, Borron SW, Hantson PE, Vicaut E, Baud FJ: Hypokalemia related to acute chloroquine ingestion. Lancet. 1995, 346: 877-880. 10.1016\/S0140-6736(95)92711-5.","journal-title":"Lancet"},{"key":"1631_CR31","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1056\/NEJM198801073180101","volume":"318","author":"B Riou","year":"1998","unstructured":"Riou B, Barriot P, Rimailho A, Baud FJ: Treatment of severe chloroquine poisoning. N Engl J Med. 1998, 318: 1-6. 10.1056\/NEJM198801073180101.","journal-title":"N Engl J Med"},{"key":"1631_CR32","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1016\/S0022-3565(24)29555-0","volume":"297","author":"JA Sanchez-Chapula","year":"2001","unstructured":"Sanchez-Chapula JA, Salinas-Stefanon E, Torres-Jacome J, Benavides-Haro DE, Navarro-Polanco RA: Blockade of currents by antimalarial drug chloroquine in feline ventricular myocytes. J Pharmacol Exptl Therapeutics. 2001, 297: 437-445.","journal-title":"J Pharmacol Exptl Therapeutics"}],"container-title":["Malaria Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/1475-2875-10-53.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,3]],"date-time":"2025-03-03T03:53:53Z","timestamp":1740974033000},"score":1,"resource":{"primary":{"URL":"https:\/\/malariajournal.biomedcentral.com\/articles\/10.1186\/1475-2875-10-53"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,3,1]]},"references-count":32,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2011,12]]}},"alternative-id":["1631"],"URL":"https:\/\/doi.org\/10.1186\/1475-2875-10-53","relation":{},"ISSN":["1475-2875"],"issn-type":[{"value":"1475-2875","type":"electronic"}],"subject":[],"published":{"date-parts":[[2011,3,1]]},"assertion":[{"value":"23 October 2010","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 March 2011","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 March 2011","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}],"article-number":"53"}}